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Abstract 
 
A wide range of screening technologies is available for colorectal cancer (CRC) screening. 
There is demand to discover public preferences for these tests on the rationale that tailoring 
screening to preferences may improve uptake. This review describes a type of study 
(conjoint analysis) used to assess people’s preferences for CRC screening tests and 
critically evaluates research quality using a recently published set of guidelines. Most 
primary studies assessed preferences for colonoscopy and faecal occult blood testing but 
newer technologies (e.g. capsule endoscopy) have not yet been evaluated. Although studies 
often adhered to guidelines, there was limited correspondence between stated preferences 
and actual screening behaviour. Future research should investigate how studies can go 
beyond the guidelines in order to improve this and also explore how test preferences may 
differ by important population subgroups.  
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Background 
 
Consensus guidelines have recommended colorectal cancer (CRC) screening for well over a 
decade [1] and Level 1 evidence has shown a consistent reduction in incidence [2-4] and 
disease-specific mortality [5]. However, screening uptake continues to languish behind other 
more established forms of screening such as for breast and cervical cancer. In England, 
uptake of biennial faecal occult blood testing (FOBt) was approximately 54% after the first 
round of screening invitations in the Bowel Cancer Screening Programme [6] compared to 
70-80% uptake of breast and cervical screening [7-8]. Similar trends are apparent in other 
countries [9]. Given that uptake is the key determinant of the health benefits of screening, 
there is clearly scope to reduce incidence and mortality further by enhancing uptake. 
Furthermore, uptake is affected by socioeconomic status, ethnicity and gender, suggesting 
that the benefits of CRC screening are disproportionally distributed among the population, 
leading to inequities in which those who are less affluent, from a non-white ethnic 
background or male do not benefit as much as others [6].    
 
A unique feature of CRC screening is the wide range of screening tests available; US 
guidelines currently endorse no fewer than seven modalities, each of which has received 
some level of empirical support for their effectiveness [10]. Test characteristics are diverse 
and it is unclear which is superior. For example, FOBt has a strong evidence base for 
reducing CRC mortality, is convenient and cheap (the test is administered at home), but its 
relative lack of sensitivity for pre-cancerous adenomas means there is no confirmed potential 
for prevention [11]. At the other extreme, colonoscopy is believed to have the most potential 
for both CRC prevention and early detection due to its ability to visualise the entire 
colorectum directly and perform therapeutic polypectomy. However, it is time-consuming for 
patients, technically demanding, expensive, and commonly involves sedation. Furthermore, 
colonoscopy has a small but well-documented morbidity [12].     
 
Why is measuring preferences important? 
 
There are three principal reasons why measuring preferences has been advocated in the 
context of CRC screening. First, knowledge of public preferences is particularly important for 
health care systems that offer a specific test via an organised screening programme. In this 
context, offering the specific test that would be preferred by the greatest number of the 
eligible population is expected to optimise uptake. There may be practical barriers to tailoring 
screening to preferences to this degree; for example, the most preferred test may be 
significantly less effective or have limited availability. However, knowledge of preferences 
has important applications since it allows estimates of screening uptake, which is necessary 
for calculating the cost-effectiveness of particular screening strategies. 
 
Secondly, preferences may also be important for systems where individuals can choose 
from a range of available tests, for example via a process of shared-decision making with a 
clinician. In this case, knowledge of public preferences could be valuable to guide 
consultations (e.g. by allowing predictions of what a given patient is likely to prefer). 
 
A third reason used to argue for a greater understanding of preferences for different 
screening modalities is that this allows public health policy makers to fulfil ethical duties of 
ensuring that screening is as acceptable as possible to screening participants, improving 
people’s satisfaction with the process. 
 
How are preferences measured?  
 
Revealed preference studies 
One of the most intuitive and commonly used methods to establish preferences is to 
measure uptake after randomising individuals to receive an offer of a single test. A meta-
analysis of 100 such studies [13] found that tests which may have been perceived as less 
invasive (e.g. stool tests or flexible sigmoidoscopy) achieved higher uptake than alternatives 
(e.g. colonoscopy or CT colonography [CTC]). Pooled uptake of stool tests was 47% and 
42% (for FOBt and faecal immunochemical testing [FIT], respectively), 35% for flexible 
sigmoidoscopy, 28% for colonoscopy and 22% for CTC. A less commonly used method to 
establish preferences is to measure uptake after offering individuals a choice of different 
modalities. For example, a trial by the Multicentre Australian Colorectal-neoplasia Screening 
(MACS) Group offered participants a choice of FOBt, FOBt combined with flexible 
sigmoidoscopy, colonoscopy, or CTC [14]. The most frequently preferred test was FOBt, a 
finding consistent with between-subjects designs. The rationale for choosing one of these 
so-called revealed preference designs over the other is guided by what would be most 
applicable to a particular healthcare system. Revealed preference studies have the 
advantage of generating reliable and easily interpreted data on preferences and the relative 
acceptability of different tests. However, the practical and financial barriers to administering 
one or more screening tests are significant and so it is often expedient to use alternative 
methodologies. 
 
One such approach that avoids these issues is the use of interviews and focus groups that 
lend themselves to qualitative methods of analysis. The open-ended nature of such designs 
allows considerable flexibility to explore a wide range of issues relating to screening uptake. 
For example, qualitative studies can be used to ask individuals with experience of screening 
(as it might already be available in a particular healthcare system) about aspects of tests that 
they found difficult or unpleasant, allowing researchers to consider methods of screening 
that might be preferable (e.g. [15]). Such studies can also be carried out with screening-
naïve individuals and may provide participants with information on different aspects of a 
particular test (e.g. its ability to detect CRC or the practicalities of what it involves) and 
investigate aspects that are likely to dissuade or encourage them to undergo it, as well as 
participants’ underlying reasons (e.g. [16]). 
 
Qualitative approaches are an effective way of allowing (potential) healthcare users to raise 
issues that researchers had not previously considered and can yield extremely detailed data 
to guide future research. However, it is normally the case that subsequent quantitative 
research is needed to confirm any findings. 
 
 
Quantitative stated preferences – Conjoint analysis 
Conjoint analysis aims to quantify potential screening participants’ willingness to undergo a 
test in a hypothetical context, without running an expensive and potentially futile trial. It also 
aims to quantify the importance of key features that determine users’ preferences.  
 
Conjoint analysis applies principles from health economics. It begins from the premise that 
the value (“utility”) of a good or service can be defined in terms of several key characteristics 
(“attributes”). For screening, one possible attribute is the preparation before the test. This 
can differ between (or within) tests and the conjoint design will specify several different 
values with the intention of capturing the full range that might be relevant (e.g. none vs. 
enema vs. oral laxatives and low fibre diet).   
 
Participants are presented with a number of scenarios involving a configuration of attributes, 
each with different levels, as part of a survey (see Figure 1. for an example). Participants are 
typically asked to make a choice between these options, which is why a common method of 
conjoint analysis is known as a discrete choice experiment. Statistical modelling is then used 
to quantify the relative importance of different attributes. In order to estimate uptake for 
options defined by a given combination of attribute levels, an “opt-out” is added to the list of 
options, allowing participants to state a preference for no testing (option C in Figure 1). 
 
------------------------------------------------Place Figure 1 here------------------------------------------------ 
 
The use of conjoint analysis studies has been gathering momentum for over a decade 
(Figure 2) and has led to the recently published set of guidelines, written by the International 
Society for Pharmaceconomics and Outcomes Research (ISPOR) on how to plan, conduct 
and analyse conjoint analysis studies [17]. 
 
Briefly, the guidelines consist of ten primary questions (each with three further secondary 
questions) that researchers are encouraged to take into account when designing conjoint 
analysis studies. They cover important issues such as study design and data collection 
strategies (Table 1). 
 
------------------------------------------------Place Table 1 here------------------------------------------------ 
 
 
------------------------------------------------Place Figure 2 here------------------------------------------------ 
 
Review aims 
We used the ISPOR guidelines to describe and evaluate key features of conjoint analysis 
studies of CRC screening tests. Primary studies were identified through a systematic search 
of several potentially relevant databases (Pubmed, CINAHL, Web of Knowledge, Embase, 
PsycINFO) for English language articles (see Table 2. for search terms). 
 
Plurals were searched for, as were both United States and United Kingdom spellings. Titles 
and abstracts were reviewed and studies were excluded if they did not refer to conjoint 
analysis, colorectal cancer or screening. Studies that did not meet these exclusion criteria 
were read in full and reference lists were scanned to identify further relevant articles. 
Remaining articles were excluded if they were reviews or evaluations of conjoint analysis 
methodology itself. 
 
 
 
------------------------------------------------Place Table 2 here------------------------------------------------- 
Overview of studies 
 
------------------------------------------------Place Table 3 here------------------------------------------------- 
 
 
Expert commentary 
 
Heterogeneity between the seven primary studies made direct comparisons difficult, despite 
the common theme of CRC screening. Most obviously, there was considerable variation in 
the specific tests that were compared and the attributes used to describe them, reflecting the 
large number of different testing options available. Furthermore, rapid development within 
the field also meant that some potential screening modalities (e.g. capsule endoscopy) have 
yet to be evaluated using this technique. 
 
Four studies estimated and compared uptake between real screening tests. The two that 
included CTC as an option found it to be the most commonly preferred modality [21-22]. 
Conversely, the two studies that did not evaluate CTC [18,20] estimated flexible 
sigmoidoscopy to have the greatest potential to increase uptake. However, flexible 
sigmoidoscopy was the least preferred test in one study [21]. In addition, stool-tests (FOBt or 
faecal DNA testing) were least preferred in three studies [18,20,22]. This illustrates the 
difficulties of trying to generalise findings across studies. 
 
Given this lack of consistency within stated preference studies, it is not surprising that similar 
discordance exists between results of stated preference findings and revealed preference 
studies. The meta-analysis described above showed that uptake of CTC compares poorly 
with other tests, despite the positive findings from two of these stated preference studies. 
Similarly, stool tests have comparatively high uptake in, despite being least preferred in 
three stated preference studies. 
 
The recently published ISPOR guidelines are a useful framework for exploring specific 
methodological strengths and weaknesses in individual conjoint analysis studies and a 
starting point for identifying some of the reasons for such discrepancies. 
 
 
Study evaluation using the ISPOR guidelines 
Study aims and perspectives 
Most primary studies were oriented around optimising uptake, either by estimating which of 
several specific screening tests (as defined by a particular set of attributes and levels) was 
preferred most or by understanding preference structures (i.e. determining the order and 
magnitude of importance of attributes). One early study aimed to determine whether it was 
possible to model utility and disutility based on screening interval (i.e. the period between 
screening invitations), CRC mortality risk reduction, test specificity (the proportion of people 
without abnormalities who are correctly categorised as such) and financial costs [24]. Other 
perspectives included improving service users’ satisfaction [19] or fulfilling an ethical duty to 
involve service users in healthcare decisions [23]. 
 
Articles were generally good in terms of defining the research question and although most 
did not state explicit testable hypotheses, aims were expressed with enough clarity that 
hypotheses could be inferred. Most studies gave a clear rationale for using conjoint analysis 
to address the research question. 
 
 
Attributes and levels 
Frequently used attributes included descriptions of what the test involves (in terms of what a 
screening participant would have to go through) [18,21-22], preparation [20-22] and pain or 
discomfort [20-22]. All studies included performance-related attributes that related to either 
accuracy (e.g. sensitivity, “unnecessary colonoscopies” or “accuracy” [21-23]) or CRC-
mortality risk reduction [18,20]). Two studies provided information on both accuracy and 
CRC-mortality risk reduction [19,23].  
 
Three studies included participants’ out-of-pocket costs as an attribute in the final survey 
[19,22,24]. Marshall et al. included this attribute in order to estimate the effect that varying 
costs would have on uptake for each test under investigation. Gyrd-Hansen and Søgaard 
and Nayaradou et al. included cost with the rationale that it is a pertinent factor in healthcare 
programmes. Salkeld et al. included this attribute during piloting but removed it as an 
insufficient number of participants expected it to encourage their participation. Remaining 
studies gave no explicit rationale for not including cost. 
 
Several attributes were defined using just two levels (e.g. location: home vs. hospital [20]; 
discomfort: none vs. some [21]). A single study defined an attribute with six levels (cost: 0; 
100; 500; 1000; 2000; 5000 Danish krone per test [24]). All attributes were defined using this 
range of 2 to 6 levels. 
 
Four studies used attributes and levels in order to define real tests [18,20-22]. Of these four, 
all defined real stool tests (guaiac FOBt, faecal immunochemical testing [FIT], or faecal DNA 
sampling), flexible sigmoidoscopy and colonoscopy. Two defined barium enema and two 
defined CTC. The remaining three studies used hypothetical tests that did not clearly relate 
to an existing screening modality, although one study described a stool test that did not 
specifically relate to guaiac FOBt, faecal immunochemical testing or faecal DNA testing. 
 
Most studies stated that literature reviews, expert advice, and/or pilot work (usually 
qualitative) were used in order to identify and select the attributes used and their levels. 
However, a common weaknesses was a lack of detail on the specifics of how attributes were 
selected based on this evidence. Similarly, studies were mixed in terms of whether they 
justified particular levels. Several provided explicit references for sources used to derive 
levels; others did not refer to specific literature. This lack of clarity also had the effect of 
reducing reproducibility. 
 
Study design 
Study design refers to considerations regarding how tasks are constructed (e.g. the number 
of alternatives per choice task), the experimental design (such as statistical considerations 
used to determine which combinations of attribute levels should make up the survey 
questions) and how preferences are elicited (e.g. asking participants to state a preference 
for a single option or to rank tests from most preferred to least preferred).  
 
Most studies added considerable value to their findings by adding an opt-out question which 
allowed an estimation of how preferences could be projected in terms of actual screening 
participation. Most of these studies presented participants with at least two profiles 
(examples of possible tests) per task and an opt-out profile representing no testing; others 
included an opt-out option without presenting it as a profile. It is possible that presenting the 
opt-out question separately, after stating a preference from a choice of tests (e.g. “would you 
have your preferred test?”) leads to more valid results compared to presenting it alongside 
the test options themselves (as in Figure 1). Breaking down the decision-making process 
into two parts may reduce participant burden and “naysaying” where participants state a 
preference for no screening as a means to avoid engaging with the question.  
 
All studies were mindful of the number of tasks they presented to participants which ranged 
from 1 to 16. The best studies conducted pilot studies to ensure that the data collection 
instrument was comprehensible and acceptable to the target population. 
 
Most studies used discrete choice tasks in which participants were asked to express a 
preference for a specific option. There were two notable exceptions that used ranking or 
rating scales [21,24]. In both cases, these atypical choices were justified. In the case of 
Hawley et al., using a rating scale was anticipated to be easier for those of lower education. 
Gyrd Hansen and Søgaard were able to carry out a more detailed analysis by combining a 
ranking task with a discrete choice task. Participants were asked whether they would have 
one of three alternatives, which one they would prefer and which their second and third 
preferences were. 
 
It was generally difficult to assess studies regarding the quality of their instructions for 
completing surveys since data collection instruments and interview schedules were not 
supplied in full. Furthermore, despite the increasing application of conjoint analysis, it is often 
necessary to provide explanations of concepts for readers of clinically based publications 
and so it may be impractical for articles to include complete experimental details. However, 
authors are now encouraged to make use of online resources to include appendices that 
enable other researchers to evaluate and replicate study methodology. 
 
 
Instrument design 
Instrument design refers to the actual full survey that participants are asked to complete. 
This includes the conjoint tasks and also any preliminary information that describes the study 
context and attributes for participants, qualifying questions (e.g. assessments of how difficult 
participants found the survey) and demographic questions (e.g. gender and age). Most 
studies introduced the study with an explanation of the context of screening as well as the 
attributes and levels under investigation.  
 
Most studies also collected appropriate respondent information. Key demographic 
characteristics were recorded on participants’ ages and gender and six studies reported 
further results that usefully characterised their sample including race or ethnicity, and 
socioeconomic status, or SES proxies such as income or education.  
 
Several studies also reported data regarding participants’ previous CRC screening history or 
other measures of exposure to CRC such as whether participants knew someone who had 
been affected. Collecting detailed information about the background of participants is useful 
when trying to determine the extent to which stated preferences are influenced or moderated 
by factors other than test characteristics. 
 
 
Data collection 
Data collection primarily refers to the mode by which the survey is administered and the 
sampling strategy. Five of the primary studies collected data from participants using pen and 
paper surveys (e.g. Hol et al.; Marshall et al. [18,22]) although two used a face-to-face 
interview [23-24]. Participants were usually identified through primary care networks or 
population registries and invited to participate via mail. Sample sizes varied from 205 to 656. 
One study [20] assessed two subgroups of screening-naïve (N=156) and previously 
screened participants (N=124). 
 
Very few studies described a power calculation and justification of sample size was 
uncommon. Although power calculations are challenging for conjoint analysis studies, some 
guides are available [25]. In addition, studies did not justify the age range of recruited 
participants. Although it could be assumed that studies sampling of older adults was related 
to the age at which risk of CRC increases (and consequently the age at which CRC 
screening is first offered), it was not always apparent whether individuals were 
eligible/recommended for screening or approaching screening age. There is evidence that 
perceptions of screening are influenced by whether an invitation is expected soon or in the 
distant future [26], which may affect the comparability of study samples. 
 
Studies were also poor in terms of justifying the chosen method of administering the data 
collection instrument. Given that there are advantages and disadvantages to various 
approaches (e.g. online or postal questionnaires vs. interview surveys), and that the best 
approach will vary depending on a particular study’s aims and priorities, it is important to 
explain why a particular approach was chosen for an individual study. 
 
 
Statistical analyses 
Studies were generally much better at ensuring the internal validity of their results. Almost all 
studies reported data on respondent characteristics and most assessed the validity of 
preference data by testing either ‘rationality’ (i.e. whether participants chose an option that 
was superior to another on all attributes over a comparator), willingness to trade (i.e. 
whether people always stated a preference for a test that was superior on a specific attribute 
and were unwilling to accept an inferior level of that attribute in exchange for a superior level 
of another attribute), and general comprehension. Most studies were good at assessing the 
quality of participants’ responses. One study assessed willingness to trade and five used 
rationality tests (or a similar comprehension test); some went further by running analyses 
with and without irrational responders. 
 
However there was clear scope for studies to explore these latter two issues in greater 
depth. For example, unwillingness to trade may be the result of participants not engaging 
with the question or a genuinely high valuation of a particular attribute. In addition, qualitative 
research has found that responses that are “irrational” under economic theory can have a 
rational basis [27]. Studies should aim to explore the nature of such responses, wherever 
practical. 
 
Most studies could have been strengthened by analysing respondent characteristics in 
detail. Crucially, most studies did not assess the extent to which the sample was 
representative of the population of interest, meaning that external validity was difficult to 
gauge. One method of testing this (used by Marshall et al. [22]) is to compare demographics 
from the sample (e.g. the ratio of males to females) with what would be expected from a 
population-representative sample based on census data. Similarly, characteristics of study 
participants and non-participants were rarely compared.  
 
Response rates could be extrapolated from all but one study [21] and showed wide variation 
from 31% [20]) to 83% [24]. It was notable that only two studies reported higher response 
rates among participants with experience of CRC screening compared to screening-naïve 
participants [18,20]. However, this is likely to be a common trend that is worth assessing 
since it is likely that the preferences of screening participants differ to those of non-
participants (e.g. they may have fewer concerns over practical barriers since they have 
previously overcome them). 
Results and conclusions 
Most studies reported models that reflected their respective hypotheses and were able to 
frame their findings in the context of wider policy or decision-making. Similarly, studies were 
generally good at reporting relevant limitations. 
 
In addition to the findings noted above, accuracy- and process-related attributes (e.g. what 
participants would have to go through) were the characteristics most commonly found to be 
the primary predictors of preferences (Table 4.).  
 
The preference structures of particular sub-groups were compared in most studies. For 
example, studies found differences between racial and ethnic groups [21]; white participants 
were more likely to rate accuracy as the most important attribute compared with African 
Americans and Hispanic participants, and African Americans were more likely to rate test 
frequency as most important compared with white and Hispanic participants.  
 
Differences were also found between previously screened and unscreened participants 
[18,20]. For example, screening-naïve participants valued the risk reduction of CRC more 
highly than those who had been screened. In addition, participants with endoscopy 
experience rated pain and hospital testing as more negative and positive respectively, 
compared to participants without endoscopy experience (full results are available in Table 5). 
There were also differences based on socioeconomic status [19] whereby participants with 
higher self-rated social class or more education valued sensitivity more than those of lower 
social class or less education. 
 
 
  
------------------------------------------------Place Table 4 here------------------------------------------------- 
 
 
------------------------------------------------Place Table 5 here------------------------------------------------- 
 
Going beyond the ISPOR guidelines 
The ISPOR guidelines offer a detailed list of important considerations which, if they are 
adhered to, will invariably improve the conduct of conjoint analysis studies. The studies in 
this review performed well on a majority of aspects although the issues regarding external 
validity were among the most significant shortcomings. However, these collective 
weaknesses were not a plausible explanation for the clear discrepancy between the findings 
of stated and revealed preference studies noted above. Consequently, there are likely to be 
several important aspects that are not addressed by the guidelines but which might need to 
be explored further. 
 
 
Oversimplified and inaccurate information.  
Conjoint analysis studies simplify the information provided to participants regarding study 
context, attributes and levels in order to reduce participant burden; it is a matter for 
researchers’ judgment to determine the level of detail provided. For example, FOBt and FIT 
differ in terms of the number of stool samples required per test, dietary restrictions, medicinal 
use, sampling and storage methods, and these factors may contribute to differences in 
uptake between the tests [28]. However, both may be described in conjoint analysis as 
simply “stool sampling”, disguising key information that could influence preferences and 
uptake. The diverse and multifaceted nature of screening tests inevitably means that some 
simplification is necessary. However, future research should explore whether the external 
validity of conjoint analysis studies could be improved by providing participants with more 
detailed information regarding the concept of screening and test attributes. It is also difficult 
to evaluate studies when the information presented to participants is not fully documented; 
data collection instruments should be made available wherever possible. 
 
In addition to oversimplification, studies may also present information which is inaccurate, 
leading to unreliable estimates. For example, although Marshall et al. [22] used existing 
literature to select levels of sensitivity for CRC that approximated various screening tests, 
specificity was assumed to be 100% for all modalities. However, false positives are an 
appreciable issue with all radiographic and stool tests [29] and since they result in 
unnecessary and inconvenient endoscopy, failing to account for this will lead to 
overestimates of value and uptake for these tests.  
 
Providing inaccurate information may also be an issue with revealed preference studies and 
population screening. For example, one trial provides evidence that participants expected a 
reduced-laxative preparation to be less burdensome than a powerful-laxative preparation but 
that experiences were more burdensome, despite the effects most likely being objectively 
less severe [30]. This suggests that the participants may have received information on 
reduced-laxative preparation that was overly positive, leading to unrealistic expectations that 
detracted from their experience. Although this study reported that a large majority of 
participants stated a willingness to repeat the experience in future, inadequate information 
may negatively affect people’s willingness to participate in future rounds of screening.  
 
 
Heuristics and biases.  
An issue overlapping with oversimplification is that study designs may inadvertently 
potentiate various heuristics and biases in participants, leading to less valid stated 
preferences. For example, studies which describe sensitivity and specificity in terms of 
percentages (of lesions found out of all possible lesions and false positives out of all patients 
without lesions) are vulnerable to “base rate neglect” [31] in which participants are not 
cognisant of the prevalence of lesions in the population to begin with. This means 
participants are unable to gauge the probability of the various outcomes of testing, leading to 
preferences based on ideas of prevalence that are either unrealistically high or not mentally 
quantified at all [32].  
 
There are also well-recognised biases that affect how people appraise identical information, 
depending on whether that information is framed as a loss or a gain [33]. Consequently, an 
attribute like specificity may be valued differently, depending on whether it is presented as 
people correctly reassured with a normal result (a gain frame) or subjected to an 
unnecessary follow-up investigation (a loss-frame). Conjoint analysis studies cannot take 
account of all possible biases. However, awareness of these issues can allow researchers to 
take steps to minimise them, where possible, such as by using an icon array showing a 
given number of people undergoing a test in which the number of people experiencing each 
of the possible outcomes is highlighted using colour-coding [34]. As with the issues around 
inaccurate information, this is relevant beyond conjoint analysis  and can be applied to 
revealed preferences studies or population screening.  
 
 
 
Hypothetical scenarios.  
One of the shortcomings of stated preference studies is that they necessarily treat intention 
to be screened as a proxy of actual behaviour. However, the gap between intentions and 
behaviour has been well documented [35]. Assessing preferences in a hypothetical context 
could also result in inaccurate conclusions regarding preference structures because people 
may value test attributes differently in a real world setting. For example, participants may 
state a preference based primarily on outcome characteristics of a test (e.g. sensitivity) in 
hypothetical situations and underestimate the extent to which process attributes would be 
barriers since they are not currently having to face them (e.g. out-of-pocket expenses, time 
expenses or discomfort). Such a bias would go some way to explain why an accurate but 
inconvenient modality such as CTC is often preferred over less onerous tests such as FOBt 
in stated preference tasks, in contrast with revealed preference studies. An important 
challenge for conjoint analysis will be to refine questions to make sure people consider 
practical barriers when stating test preferences. One possible method of exploring these 
issues in further detail is the use of qualitative methods within conjoint analysis studies. 
Gyrd-Hansen & Søgaard provide an example of how a qualitative component can be used to 
improve understanding of quantitative responses; this could be extended to explore how 
participants incorporate complex information into their decision-making. Similarly, it would be 
useful to apply these methods to screening participants for comparison. It may also be 
helpful to learn more about why research in other healthcare contexts (e.g. chlamydia 
screening) has found much better concordance between stated and revealed preferences 
[36]. 
 
 
Understanding sub-group differences.  
Future conjoint analysis research may also investigate how test preferences vary by relevant 
population demographics, in particular race, socioeconomic status and gender. For example, 
Hawley et al. [21] found that white participants were more likely to rate accuracy as the most 
important attribute compared to other racial and ethnic groups, whereas other racial/ethnic 
groups were more likely to rate frequency as most important. Consistent with this, a study of 
revealed preferences by Inadomi et al. [37] found that white participants randomised to 
either an offer of FOBt, colonoscopy, or choice between the two, adhered more often to the 
more accurate colonoscopy whereas non-white invitees adhered more often to FOBt. Future 
research regarding subgroup preferences will be directly applicable to national screening 
policy. 
 
Although the focus of this review has been CRC screening tests, all the issues described 
above could apply to conjoint analysis in general and so concerns may be equally applicable 
to studies investigating preferences for other medical technologies or healthcare delivery 
[38]. 
 
 
Five-year view 
 
CRC screening strategies are in a state of flux globally as new tests and evidence continue 
to emerge and the policy landscape continues to shift. In the United Kingdom, several 
changes to the existing screening programme are taking place. Most notably, pilots are 
being established that offer one-off flexible sigmoidoscopy to the population aged 55-59, 
following a randomised trial that found reductions in both disease-specific incidence and 
mortality [4]. These results have since been supported by a trial in the United States [2] and 
Italy [3]. Furthermore, the existing UK programme of biennial stool testing is converting from 
guaiac FOBt to FIT and this change is planned to occur parallel with the incoming flexible-
sigmoidoscopy programme. The upper age range at which people will be invited to have 
stool testing is also being extended to 74, beyond the current upper age range of 69.  
In the United States, the Patient Protection and Affordable Care Act is likely to have wide-
ranging impact on CRC screening. It is estimated that an additional 32-50 million individuals 
will receive health insurance because of the Act, substantially reducing barriers to access of 
screening tests [39]. In addition new colorectal tests such as capsule endoscopy are 
continuing to emerge and may warrant consideration for screening [40]. 
 
Measuring test preferences will continue to be an important part of meeting policy goals 
while these changes are implemented and conjoint analysis is likely to play a role. In order to 
do so effectively, conjoint analysis should be as robust as possible. 
 
 
Key issues 
 
 
•  Screening for colorectal cancer has been shown to be effective at reducing disease 
specific mortality and a number of viable tests have been mooted. However, uptake of CRC 
screening is poor compared with other more established cancer screening strategies. 
 
•  Offering screening tests that are consistent with service users’ preferences and values 
may improve uptake, optimising reductions in disease-specific incidence and mortality. 
 
•  Stated preference studies such as conjoint analysis are a low cost means of assessing 
users’ preferences. 
 
•  When reviewed in accordance with recent ISPOR guidelines, previous conjoint analysis 
studies of colorectal cancer screening demonstrate a number of strengths and weaknesses. 
 
•  Inconsistencies between revealed and stated preferences are an important issue that 
needs to be resolved, requiring considerations beyond the guidelines. 
 
 •  Studies that evaluate preferences for CRC screening tests using conjoint analysis should 
explore whether stated preferences would be more consistent with revealed preferences if a 
greater level of detail regarding tests and screening context were provided, strategies to 
reduce heuristics and bias were introduced and participants were encouraged to consider 
important motivators and barriers fully. 
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Figure 1. An example choice scenario, reproduced from van Dam et al. [20] 
 
**Colour** Figure 2. Cumulative total of PubMed articles containing the term “conjoint 
analysis”. 
 
0
50
100
150
200
250
300
350
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
C
u
m
u
la
ti
ve
 p
u
b
lic
at
io
n
s 
Year 
**Black & White** Figure 2. Cumulative total of PubMed articles containing the term “conjoint 
analysis”.
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Table 1. Reproduced from Bridges et al. [17] 
   
  Table 1 – A checklist for conjoint analysis applications in health care. 
    1. Was a well-defined research question stated and is conjoint analysis an appropriate method for answering it? 
        1.1 Were a well-defined research question and a testable hypothesis articulated? 
        1.2 Was the study perspective described, and was the study placed in a particular decision-making or policy context? 
        1.3 What is the rationale for using conjoint analysis to answer the research question? 
    2. Was the choice of attributes and levels supported by evidence? 
        2.1 Was attribute identification supported by evidence (literature reviews, focus groups, or other scientific methods)? 
        2.2 Was attribute selection justified and consistent with theory? 
        2.3 Was level selection for each attribute justified by the evidence and consistent with the study perspective and hypothesis? 
    3. Was the construction of tasks appropriate? 
        3.1 Was the number of attributes in each conjoint task justified (that is, full or partial profile)? 
        3.2 Was the number of profiles in each conjoint task justified? 
        3.3 Was (should) an opt-out or a status-quo alternative (be) included? 
    4. Was the choice of experimental design justified and evaluated? 
        4.1 Was the choice of experimental design justified? Were alternative experimental designs considered? 
        4.2 Were the properties of the experimental design evaluated? 
        4.3 Was the number of conjoint tasks included in the data-collection instrument appropriate? 
    5. Were preferences elicited appropriately, given the research question? 
        5.1 Was there sufficient motivation and explanation of conjoint tasks? 
        5.2 Was an appropriate elicitation format (that is, rating, ranking, or choice) used? Did (should) the elicitation format allow for indifference? 
        5.3 In addition to preference elicitation, did the conjoint tasks include other qualifying questions (for example, strength of preference, 
              confidence in response, and other methods)? 
    6. Was the data collection instrument designed appropriately? 
        6.1 Was appropriate respondent information collected (such as sociodemographic, attitudinal, health history or status, and treatment 
              experience)? 
        6.2 Were the attributes and levels defined, and was any contextual information provided? 
        6.3 Was the level of burden of the data-collection instrument appropriate? Were respondents encouraged and motivated? 
    7. Was the data-collection plan appropriate? 
        7.1 Was the sampling strategy justified (for example, sample size, stratification, and recruitment)? 
        7.2 Was the mode of administration justified and appropriate (for example, face-to-face, pen-and-paper, web-based)? 
        7.3 Were ethical considerations addressed (for example, recruitment, information and/or consent, compensation)? 
    8. Were statistical analyses and model estimations appropriate? 
        8.1 Were respondent characteristics examined and tested? 
        8.2 Was the quality of the responses examined (for example, rationality, validity, reliability)? 
        8.3 Was model estimation conducted appropriately? Were issues of clustering and subgroups handled appropriately? 
    9. Were the results and conclusions valid? 
        9.1 Did study results reflect testable hypotheses and account for statistical uncertainty? 
        9.2 Were study conclusions supported by the evidence and compared with existing findings in the literature? 
        9.3 Were study limitations and generalizability adequately discussed? 
    10. Was the study presentation clear, concise, and complete? 
        10.1 Was study importance and research context adequately motivated? 
        10.2 Were the study data-collection instrument and methods described? 
        10.3 Were the study implications clearly stated and understandable to a wide audience? 
 
Table 2. Search strategy 
 
Retrieved articles contained these words: 
 
Conjoint analysis, discrete choice, discrete ranking or stated preference 
 
And 
 
Colonoscopy, CT colonography, 
barium enema, endoscopy, 
flexible sigmoidoscopy, faecal 
occult, faecal immunochemical or 
faecal DNA 
Or Bowel, colon, colorectal or 
rectal 
 
And 
 
Cancer, neoplasm or malignancy 
 
And 
 
Screening 
 
Table 3. Description of conjoint analysis studies included in this review. 
Study Country Aims Study sample 
Hol et al. 2010        
[18] 
Holland “Determine individuals’ preferences and to predict the uptake of CRC screening 
programmes with various screening tests, and the relative importance of different 
test characteristics for these preferences in an average-risk population [and] to 
identify differences in preference structures among subgroups in the population.” 
One group of screening-naïve individuals 
aged 50-74. One group of participants 
aged 50-74 who had been screened as 
part of a screening trial. 
Nayaradou et al. 2010 
[19] 
France “Our study aims at empirically identifying population preferences among the 
different characteristics of a mass CRC screening programme.” 
Members of the general population aged 
50-74. 
van Dam et al. 2010 
[20] 
Holland “Determine how procedural characteristics of CRC screening tests determine 
preferences for participation, and how individuals weigh these against the expected 
health benefits from CRC screening.” 
One group of screening-naïve 50-74 year 
olds. One group of participants in a 
screening trial. 
Hawley et al. 2008  
[21] 
United States “The specific research objectives were (1) to describe preferences for CRC 
screening tests among African American (AA), Hispanic, and white primary care 
patients; and (2) to evaluate factors associated with preferences for guideline-
recommended (eg, FOBT, SIG, COL, BE) and new technology (eg, FIT, V-COL) 
screening options in this diverse population.” 
African-American, Hispanic and White 
primary care patients aged 50-80 with no 
personal or family history of CRC. 
Marshall et al. 2007 
[22] 
Canada “The objective of the current study was to measure and quantify Canadian 
preferences for various CRC screening tests and for a “no-screening” option using 
utility-based methods.” 
Primary care patients aged 40-60 with no 
history of CRC, who were not 
institutionalised and understood sufficient 
English. 
Salkeld et al. 2003  
[24] 
Australia “The aim of the present study was to assess community decisions about CRC 
screening based on the trial evidence on harms and benefits.” 
Eligible CRC screening population aged 
50-70 years who had completed an earlier 
rating exercise as part of the survey 
design.  
Gyrd-Hansen & 
Søgaard 2001         
[24] 
Denmark “This paper seeks to establish a representative utility function for cancer screening 
programmes which incorporates the utility and disutility associated with intangible 
effects [harms and benefits of screening]...The analysis is basically explorative, and 
seeks to establish whether public preferences exist for attributes associated with 
participation in cancer screening programmes.” 
Population aged 50. 
 
Table 4. Summary results of conjoint analysis studies included in this review. 
Study Main findings 
Hol et al.[18] Significant predictors of preferences were type of screening test, screening interval and CRC 
mortality risk reduction. 5 or 10 yearly FS screening were both rated as preferable compared to 
10 yearly colonoscopy or yearly FOBt. 
 
Nayaradou et al. [19] Mortality reduction, sensitivity, monetary cost and process were significant predictors of 
preferences. 
 
van Dam et al. [20] Pain, risk of complications, screening location, preparation, duration of procedure, screening 
interval and risk reduction of CRC-related death all influenced preferences. An extra 1% risk 
reduction in the CRC mortality was rated as equivalent to an additional 10 minutes of test 
duration, 5% was equivalent to a small risk of adverse effects, 10% to mild pain, 10% to an 
enema, 12% to oral preparation including fasting and 32% to preparation with additional fluid and 
fasting. 
 
Hawley et al. [21] 37% of participants preferred colonoscopy, 31% preferred FOBt, 15% preferred barium enema 
and 9% preferred FS. When newer tests were included (CTC and FIT), these were rated more 
highly than existing tests. The most important attribute was what the test involved, followed by 
accuracy, frequency, discomfort and preparation. 
Marshall et al. [22] CTC was the most preferred test; the order of preferences for the remaining tests was 
colonoscopy, barium enema, flexible sigmoidoscopy and faecal DNA testing. 28.9% of 
participants consistently stated that they would prefer no screening. Attributes related to accuracy 
were more important than attributes related to process. 
Salkeld et al. [23] 32% made decisions based only on the attribute of the number of CRC deaths prevented. 12% 
always chose no screening. Remaining participants would accept 853 false positives for one life 
saved from CRC death. 
Gyrd-Hansen  
& Søgaard [24] 
Increasing cost and number of screening tests over a lifetime had a negative impact on 
preferences. Increasing risk reduction of CRC-mortality had a positive impact on preferences. 
34% preferred no screening. 
 
Table 5. Summary of main subgroup differences between previously screened and unscreened participants (and between participants previously screened 
with different tests) 
Hol et al. 
2010 [18] 
Screening-naïve participants vs. previously screened participants: The rationality test was less likely to be passed by screening-naïve participants 
compared to previously screened participants.  All screening tests were preferred less by screening-naïve participants than previously screened participants.  A 
longer screening interval was valued more highly by screening-naive participants than previously screened participants. 
Participants with experience of endoscopy vs. participants without (including participants with experience of FOBT): Preferences were more positive 
towards colonoscopy in participants with experience of FS or colonoscopy.  Preferences were more positive towards FS and colonoscopy in participants with 
experience of FS than those with experience of FOBT. 
van Dam et 
al. 2010 [20] 
Screening-naïve participants vs. CRC screening participants: Risk-reduction of CRC death was valued more highly by screening-naïve participants than 
CRC screening participants.  
Participants screened with flexible-sigmoidoscopy vs. participants screened with FOBt: A hospital-based test was preferred by FS screening 
participants. A home-based test was preferred by FOBt screening participants.  A longer screening interval and a greater risk-reduction were valued more 
highly by FS screening participants than FOBt screening participants. 
Participants with previous endoscopy experience vs. participants without: Pain was a more important attribute to participants with experience of 
endoscopy than those without.  Hospital testing was positively associated with preferences for those with experience but a negative effect on participants 
without experience.  Risk-reduction was valued less highly by participants without experience than those with experience. 
 
